Type 2 diabetes: target HbA1c of about 7%.
A 17-year follow-up study of patients with type 2 diabetes enrolled in the Ukpds trial has shown that glycaemic control targeting HbA1c levels of about 7% is associated with lower mortality.
D048909:Diabetes Complications / Q000097:blood / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D003925:Diabetic Angiopathies / Q000097:blood / Q000517:prevention & control*; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012016:Reference Values
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin